SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (942)6/3/1997 11:49:00 AM
From: Richard Belanger   of 1762
 
Brad, regarding the wide range of estimated FY98 earnings, it appears that C2B8 will be essentially unchallenged as a treatment for relapsed low-grade or follicular NHL for roughly 14-16 months following approval (assuming BLA for Coulter's Bexxar is filed and approved on schedule). Can we assume, then, that the major uncertainty involves the extent that C2B8 will be accepted as a treatment for other-than-relapsed NHL?

Regarding the sustainability, Bexxar has been shown to be more efficacious than C2B8, and I would imagine be indicated for cases of large tumor mass. However, we do not yet know how Bexxar will stand up against Y2B8. With respect to the radiological properties (Bexxar's Iodine-131 vs. Y2B8's Yttrium-90), I like what I see in the Idec product.

Thanks in advance.

Rich
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News